Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) CFO Tobin Schilke sold 1,000 shares of the stock in a transaction on Friday, January 20th. The shares were sold at an average price of $31.00, for a total value of $31,000.00. Following the completion of the transaction, the chief financial officer now owns 57,877 shares in the company, valued at $1,794,187. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Tobin Schilke also recently made the following trade(s):
- On Monday, January 9th, Tobin Schilke sold 3,701 shares of Revance Therapeutics stock. The shares were sold at an average price of $27.16, for a total value of $100,519.16.
Revance Therapeutics Stock Up 5.7 %
RVNC traded up $1.81 during trading hours on Monday, hitting $33.51. 2,967,806 shares of the company’s stock were exchanged, compared to its average volume of 2,638,715. Revance Therapeutics, Inc. has a 1-year low of $11.27 and a 1-year high of $34.22. The stock’s 50-day moving average is $22.52 and its two-hundred day moving average is $22.11. The company has a debt-to-equity ratio of 2.60, a quick ratio of 5.33 and a current ratio of 5.56.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of RVNC. ProShare Advisors LLC grew its stake in shares of Revance Therapeutics by 3.8% in the third quarter. ProShare Advisors LLC now owns 14,057 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 516 shares in the last quarter. Amalgamated Bank grew its position in shares of Revance Therapeutics by 5.0% in the 3rd quarter. Amalgamated Bank now owns 11,607 shares of the biopharmaceutical company’s stock valued at $313,000 after acquiring an additional 555 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of Revance Therapeutics by 1.4% during the 3rd quarter. UBS Asset Management Americas Inc. now owns 69,815 shares of the biopharmaceutical company’s stock worth $1,885,000 after purchasing an additional 983 shares during the last quarter. Guggenheim Capital LLC raised its holdings in shares of Revance Therapeutics by 2.9% in the 1st quarter. Guggenheim Capital LLC now owns 36,805 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 1,043 shares during the period. Finally, Advisor Group Holdings Inc. lifted its stake in Revance Therapeutics by 60.6% in the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,071 shares during the last quarter. 82.68% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on RVNC. Morgan Stanley dropped their price objective on Revance Therapeutics from $27.00 to $25.00 and set an “equal weight” rating for the company in a report on Wednesday, November 9th. Guggenheim increased their price objective on shares of Revance Therapeutics to $36.00 in a report on Tuesday, November 15th. StockNews.com lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. Needham & Company LLC boosted their price objective on shares of Revance Therapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, January 10th. Finally, Barclays increased their target price on shares of Revance Therapeutics from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Wednesday, November 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.20.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
- Get a free copy of the StockNews.com research report on Revance Therapeutics (RVNC)
- Can We Trust The Rally In The S&P 500
- Energy Surge: Four Oil-And-Gas Stocks Setting Up In Bullish Bases
- One ETF Trading Strategy to Beat the Market in 2023
- Is Wayfair Still Way Cheap For Investors?
- When Does Pfizer Become A Bargain?
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.